Proof of Concept Study for Safety and Efficacy of EDP239 in Hepatitis C Subjects

NCT01856426 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

28

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatitis C

Interventions

DRUG: EDP239
DRUG: Placebo

Sponsor

Enanta Pharmaceuticals, Inc